Axonal growth cones read cues in their environment that guide them to their target. Metalloproteases have been implicated in vitro in modulating the interaction of these cues with receptors in the growth cone. To determine whether metalloprotease function is important in the guidance of vertebrate axons in vivo, we applied hydroxamate-based metalloprotease inhibitors to Xenopus retinal ganglion cell (RGC) axons as they extended through the optic tract. In the presence of two different inhibi-
The growth cone, a motile structure found at the tip of developing axons, reads cues in its environment to extend and reach its target. The presentation and transduction of these cues depend on additional molecules both intrinsic and extrinsic to the growth cone. In particular, metalloproteases have been implicated recently in vitro in modulating the interaction of guidance cues with their receptors (Zuo et al., 1998; Galko and Tessier-Lavigne, 2000; Hattori et al., 2000) .
Metalloproteases are zinc-dependent proteolytic enzymes that include the matrix metalloprotease (MMP) and the A disintegrin and metalloprotease (ADAM) families. The former contains at least 26 members and is implicated in remodeling the extracellular matrix in diverse biological processes and in several pathologies of the CNS (Yong et al., 2001) . Unlike most MMP family members, the majority of ADAM proteins are transmembrane. The ADAMs, of which there are at least 30, are unique in that they contain a cell-adhesion domain in addition to their proteolytic domain (Schlondorff and Blobel, 1999) .
Both MMP and ADAM family members are expressed in the developing CNS (Vaillant et al., 1999; Yong et al., 2001) . Their importance during key developmental processes such as neurogenesis, myelination, neuronal migration, and axon guidance is just starting to be elucidated (Yong et al., 2001) . Early studies suggested a role for metalloproteases in axon elongation (Pittman, 1985; Machida et al., 1989; Sheffield et al., 1994) . More recent tissue culture data suggest that metalloproteases regulate the signaling downstream of axon guidance cues through the cleavage of the ectodomains of several known guidance cues and receptors (Galko and Tessier-Lavigne, 2000; Hattori et al., 2000) . Together, these in vitro data suggest that metalloproteases play roles in directing the trajectories of developing axons; however, in vivo evidence has been lacking.
To investigate whether metalloproteases regulate axon guidance in vivo, we concentrated on the growth and guidance of retinal ganglion cell (RGC) axons in the developing visual system of the frog Xenopus laevis. The Xenopus visual system has been well characterized (Chien and Harris, 1994) , and the role of candidate molecules in the guidance of axons can be readily tested in vivo using an exposed brain preparation (Chien et al., 1993; McFarlane and Pollock, 2000) . Several metalloproteases have been cloned in Xenopus; these include members of both the MMP and ADAM families (Alfandari et al., 1997; Piccolo et al., 1997; Yang et al., 1997; Cai et al., 1998; Goodman et al., 1998; Carinato et al., 2000) . Many of these are expressed in the developing Xenopus embryo. Indeed, ADAM13 has been implicated recently in the migration of Xenopus cranial neural crest cells (Alfandari et al., 2001) .
In this study, we have used hydroxamate-based inhibitors to modulate the activity of metalloproteases in vivo as Xenopus RGC axons extend through the brain to their main midbrain target, the optic tectum. We find that severe disruption of axon guidance occurs as a result. Axon extension was also impaired but was less sensitive to metalloprotease inhibition.
MATERIALS AND METHODS
Animals. Eggs were obtained from adult female X. laevis stimulated with human chorionic gonadotropin (Intervet C anada L td., Whitby, Ontario, C anada), and fertilized in vitro (Sive et al., 2000) . Embryos were raised in 0.1ϫ Marc's modified Ringer's solution (Sive et al., 2000) at 20 -25°C and staged according to the Nieuwkoop and Faber (1994) staging tables.
Bathing media and metalloprotease block ers. The exposed brain preparation was performed as described previously (Chien et al., 1993) . Briefly, embryos were anesthetized in modified Barth's solution (MBS) supplemented with 0.4 mg /ml tricaine (ethyl 3-aminobenzoate methanesulfonic acid; Aldrich, Milwaukee, W I), 50 mg /ml gentamicin sulfate (Sigma, Oakville, Ontario, C anada), and 10 mg /ml Phenol Red (Sigma). The embryos were pinned in a Sylgard dish (Dow Corning, Midland, M I), and the skin and dura covering the left brain was removed. This procedure exposes the entire anterior brain on one side, reaching as far caudal as the posterior optic tectum. After surgery, the embryos were randomly divided into two groups and were allowed to develop in either experimental or control solutions for another 18 -24 hr until they reached stage 40. To block metalloproteases, hydroxamate-based inhibitors were added to the control MBS (pH 7.4) solution:
-methylpantanoyl]-L-tryptophan methylamide (GM6001) (Calbiochem, San Diego, CA) and 0.1-5 M batimastat (BB-94; British Biotech, Oxford, UK). In a separate series of experiments, the specificity of GM6001 was tested using N-t-butoxycarbonyl-L-leucyl-L-tryptophan methylamide (C albiochem), a closely related compound, as a negative control.
V isualization of the optic projection. The optic projection was visualized by anterogradely labeling RGC axons using horseradish peroxidase (HRP, type V I; Sigma) as described previously. Briefly, the lens of the right eye was surgically removed and HRP dissolved in 1% lysolecithin was placed in the eye cavity (Cornel and Holt, 1992) . Embryos were fixed overnight in 4% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. Dissected brains were washed in PBS, reacted with diaminobenzidine (Sigma), dehydrated through a graded series of alcohols, and cleared in 2:1 benzyl benzoate:benzyl alcohol. Whole-mount brains were mounted in Permount (Fisher Scientific L td., Nepean, Ontario, C anada) under a coverslip supported by two plastic reinforcement rings (Avery Office Products C anada, Bowmanville, Ontario, C anada). The outlines of brains and optic projections were drawn using a camera lucida attachment on a Z eiss (Thornwood, N Y) microscope. Digital images of preparations were taken using a Spot II camera (Diagnostic Instruments, Sterling Heights, M I) and processed for brightness and contrast with Adobe Photoshop 4.0 software (Adobe Systems, San Jose, CA).
Quantification of optic projection length and turning angle. The effects of metalloprotease inhibitors were quantified by measuring the length and turning angle of optic projections in control and treated brains. C amera lucida representations of mounted brains were scanned with an Astra 1200s flatbed scanner (Umax, Freemont, CA) to provide digital images. Samples were used only if they were mounted without significant rolling and had well filled optic projections. Analysis was performed using the public domain N IH Image program. Brains were normalized using macro programs described previously (Chien et al., 1993) by rotating and scaling them to a line drawn between the anterior optic chiasm and the midbrain -hindbrain isthmus. This line was matched to a standard reference line, artificially defined as 1 brain reference unit (b.r.u.); 1 b.r.u. is ϳ620 m in an unfixed brain (Chien et al., 1993) . The optic chiasm and the isthmus were chosen as easily identified and reliable morphological markers in the Xenopus brain. The reference line was divided into 0.1 intervals through which concentric circles were drawn. The optic-tract length was measured from the optic chiasm to the end of the optic projection containing at least 1% of RGC axons (Ͼ10 axons). The angle through which the optic projection makes a turn in the mid-diencephalon was also measured (see Fig. 3A) . A line was drawn at a 60°angle to the reference line between the optic chiasm and the midbrain -hindbrain isthmus, bisecting the optic tract at the level of the turn made in the mid-diencephalon. The angle between this line and a line drawn through the middle of the projection that runs dorsal to this line was measured. Unless otherwise stated, samples were compared statistically using an unpaired ANOVA, followed by a Student-Newmann -Keuls multiple comparison post hoc test (Instat; GraphPad Software Inc., San Diego, CA).
Retinal cell cultures. Eye primordia were dissected from stage 24 embryos and cultured as described previously (Harris and Messersmith, 1992) . Briefly, dissociated cells or entire eyes were plated onto polyornithine/ laminin-coated coverslips in 35 mm Petri dishes containing culture media. Culture media consisted of 60% L15-glutamine (Invitrogen, San Diego, CA) supplemented with 5% fetal bovine serum (Invitrogen), penicillin -streptomycin (Invitrogen), and 1% embryo extract. E xplant cultures were used for immunohistochemistry and analysis of growth cone morphology.
Immunoc ytochemistr y. Frozen transverse sections (12 m) were cut through the eyes and brain of exposed embryos. The sections were immunolabeled with mouse monoclonal antibodies against ADAM10 (1:200; Chemicon, Temecula, CA), Islet-1 (394D5, 1:100; Developmental Studies Hybridoma Bank, University of Iowa, Iowa C ity, IA), neural cell adhesion molecule (NCAM) (6F11, 1:10; Developmental Studies Hybridoma Bank), ␤-tubulin (1:1000; Sigma), 3CB2 (1:10; Developmental Studies Hybridoma Bank), neurofilament (RMO270, 1:400; Zymed, San Francisco, CA), Z n-12 (1:10; Developmental Studies Hybridoma Bank), and Deleted in Colorectal C ancer (DCC, 1:20; Oncogene, Boston, M A). A rabbit polyclonal antibody that recognizes GABA (1:3000; Sigma) was also used. Rhodamine-conjugated secondaries (Jackson ImmunoResearch, West Grove, PA) were used at a dilution of 1:500. In a separate series of experiments, 12 m cryostat sections through the midbrain and forebrain of control embryos or those treated with 5 M GM6001 were processed for DCC immunocytochemistry. For each sample, the intensity of labeling in the neuropil of at least three adjacent sections was measured using N IH Image. The background staining intensity of an unlabeled portion of the section was subtracted from the neuropil measurement.
Western blot anal ysis. Stage 42 Xenopus head tissue was homogenized in 120 mM Tris, pH 6.8, 10 mM EDTA, 0.1 mg /ml RNase A (Amersham Biosciences, Baie d'Urfe, Quebec, C anada), and 1 mM phenylmethylsulfonyl fluoride (Sigma). The homogenate was then centrif uged at 16,000 ϫ g (4°C) for 10 min. The supernatant was removed and diluted appropriately in SDS sample buffer (SDS, bromophenol blue; L K B, Bromma, Sweden), Tris-HC l, and glycerol (BDH Chemicals, Toronto, C anada) containing DTT (Sigma). Samples were boiled for 5 min and run on a 10% SDS -polyacrylamide resolving gel. After electrophoresis, proteins were electrolytically transferred to poly vinylidene difluoride membranes (Bio-Rad, Hercules, CA). The membranes were blocked in Tris-buffered saline (TBS) containing 0.05% T ween 20, 1% bovine serum albumin (Sigma), and 1% dry milk powder and incubated overnight at 4°C in fresh blocking solution containing ADAM10 primary antibody (1:1000 dilution). The membranes were rinsed in TBS with 0.2% T ween 20 and incubated for 1 hr in a peroxidase-conjugated mouse anti-rabbit secondary antibody (Jackson ImmunoResearch). Protein bands were detected with ECL reagents per the manufacturer's instructions (Amersham Biosciences).
RESULTS

RGC axon guidance defects occur in the presence of a metalloprotease inhibitor
To determine whether metalloproteases are important in the guidance of axons in vivo, we applied a hydroxamate-based metalloprotease blocker to the developing optic projection using a previously described exposed brain preparation (Chien et al., 1993; McFarlane et al., 1995) . The skin and dura are removed from one side of the brain of a stage 33/34 embryo, as the first axons from the contralateral eye cross the optic chiasm to reach the diencephalon. Optic axons grow close to the pial surface and are therefore exposed to the metalloprotease blocker over the entire course of their growth through the diencephalon toward the optic tectum. Axons are anterogradely labeled with HRP at stage 40, the stage at which the majority will have reached the optic tectum in control brains (Fig. 1 A) . Using this preparation, it is possible to determine whether a drug known to inhibit metalloprotease function affects the extension, pathfinding, and/or target recognition of developing RGC axons.
The broad-spectrum metalloprotease inhibitor GM6001 blocks the proteolytic activity of both MMP and ADAM family members. GM6001 application, at concentrations used previously in in vitro studies (Alexander et al., 2001; Karsdal et al., 2001) , had a dose-dependent effect on both the extension and the guidance of the optic tract in vivo. At a low 0.5 M GM6001 dose, the optic projections resembled those of control embryos (Fig. 2) . However, at 1 and 10 M GM6001, 59% (13 of 22) and 100% (24 of 24) of the optic projections, respectively, showed some abnormality, compared with only 4% (1 of 28) in controls (Figs. 1C-G, 2). In 27% of the brains treated with 1 M GM6001, the majority of RGC axons failed to make the turn in the mid-diencephalon ( Fig.  1C -E) and instead continued growing straight, often crossing the dorsal midline (Figs. 1G, 2) . At higher doses, 85% of the optic projections failed to turn (Fig. 2) . In addition, some axons showed aberrant growth into the telencephalon (Fig. 1 F) and/or their extension was impaired (Figs. 1 F, 2) .
Defects in innervation of the optic tectum were also observed in GM6001-treated embryos. In control embryos, axons grew into the optic tectum in a directed manner and then branched and arborized in the anterior tectum (Figs. 1 A,B, 2) . In contrast, the optic tectum was not innervated in 64.6% (n ϭ 22) and 95.8% (n ϭ 24) of 1 and 10 M GM6001-treated optic projections, respectively. In cases in which RGC axons turned in the middiencephalon and reached the border of the optic tectum, the majority of axons ignored the target entirely and instead grew along its anterior border in 43% (6 of 14) and 89% (8 of 9) of 1 and 10 M GM6001-treated optic projections, respectively (Fig. 1 D) .
To quantify both the extension and the pathfinding defects observed with the GM6001 inhibitor, the angle through which axons turn at the mid-diencephalon and the length of the optic projection were measured (Fig. 3) . A dose-dependent effect on both parameters was observed. Interestingly, these data suggest that blocking metalloprotease activity had a significant effect on axon pathfinding at concentrations at which axon outgrowth was impaired only moderately. Indeed, there were many examples in which axons clearly failed to turn in the mid-diencephalon but were not obviously impaired in their outgrowth (Fig. 1C-E) .
To test the specificity of the effect of GM6001, we used a closely related L-tryptophan methylamide compound that does not in- Defects in RGC axon pathfinding and target recognition caused by the application of GM6001. A qualitative description of the different defects in axon behavior observed in optic projections treated with different doses of GM6001 is given. Numbers in parentheses represent the number of embryos. % Abnormal is the percentage of embryos with some defect in the optic projection; % Failure to Turn refers to optic projections in which the majority of axons show a guidance defect in the mid-diencephalon, where RGC axons normally make a caudal turn toward the optic tectum; % Extension Defect refers to a shortened optic projection; % Normal Target Innervation means that the majority of RGC axons enter the optic tectum; % Midline Crossing refers to axons that extend aberrantly across the dorsal midline into the contralateral brain.
hibit metalloprotease activity and serves as a negative control (Galko and Tessier-Lavigne, 2000) . The GM6001 negative control had no obvious effect on the optic projection compared with control (Fig. 4 A,B) . Indeed, the average axon length and turning angle were not significantly different from those of control-treated projections (Fig. 4C,D) .
The metalloprotease inhibitor BB-94 also causes defects in axon extension and guidance
To test the specificity of the GM6001 effect for metalloproteases, we treated the optic projection with a second metalloprotease inhibitor, BB-94 (Brown, 1998) . BB-94 is a broad-spectrum metalloprotease inhibitor that blocks members of both the MMP and ADAM families. BB-94 had effects similar to those of GM6001 on RGC axon pathfinding, target recognition, and axon extension (Figs. 5, 6 ). Defects in axon guidance were observed with BB-94 concentrations comparable with those used previously in cell culture studies (Parvathy et al., 1998; Nath et al., 2001) . At a concentration of 0.1 M, BB-94 had little or no effect on the optic projection (Figs. 5A, 6 ). In contrast, with doses of Ն0.5 M, defects in axon extension and in the ability of RGC axons to make the turn in the mid-diencephalon were observed (Figs. 5B-D,  6 A) . The effect of BB-94 on these two parameters was quantified and is shown in Figure 6 B,C. As with GM6001, significant defects in axon turning were observed at lower BB-94 concentrations than was required to inhibit axon extension.
Inhibitors may act on metalloproteases expressed by cells lining the optic tract or in RGC growth cones GM6001 and BB-94 could act on metalloproteases expressed by neuroepithelial cells lining the optic tract, and/or RGC growth cones themselves. Consistent with this, metalloproteases have been found previously in both the developing rodent optic nerve and the RGC layer (Canete Soler et al., 1995; Agapova et al., 2001) . In Xenopus, MMPs and ADAMs are present in the developing eye primordium and/or forebrain (Alfandari et al., 1997; Pan and Rubin, 1997; Cai et al., 1998; Damjanovski et al., 2000) . Notably, mutants of the Drosophila ADAM10 ortholog kuzbanian Figure 3 . Quantitation of the effects of GM6001 on axon guidance and extension. Control and GM6001-treated brains were exposed at stage 33/34 and fixed at stage 40. Camera lucida representations of the brains and optic projections were normalized; two features of each optic projection were measured: length and the angle of the turn made in the mid-diencephalon. A, To measure the turning angle, a line (L2) was drawn at a 60°angle ( 1 ) to a standard reference line (L1) between the optic chiasm and the midbrain-hindbrain isthmus, bisecting the optic tract at the level of the turn made in the mid-diencephalon. The turning angle ( 2 ) was measured between L2 and a third line (L3) drawn through the middle of the distalmost portion of the optic projection. Measurements are shown for a control exposed brain ( A) and a metalloprotease inhibitor exposed brain ( B). C, Mean turning angle in control embryos and embryos treated with different doses of GM6001. D, Effects on optic projection length (in micrometers) of increasing doses of the GM6001. Tract length was measured in normalized b.r.u.s and then converted to micrometers (1 b.r.u. Х 620 m in an unfixed brain) (Chien et al., 1993) . At lower concentrations, at which defects in pathfinding are observed, the extension of RGC axons is only moderately affected by GM6001. At the highest concentrations of GM6001, the optic projection is significantly shorter than in control exposed brains. *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001; ANOVA, Student-Newmann-Keuls post hoc test. The numbers of embryos are shown in parentheses, and error bars are SEM.
(kuz) exhibit axon stalling defects (Fambrough et al., 1996) , and Xenopus kuz mRNA is expressed at early tailbud stages in the forebrain and the eye (Pan and Rubin, 1997) . However, it is unknown whether Xenopus KUZ protein (XKUZ) continues to be expressed as the first RGC axons reach the turn in the mid-diencephalon, the site where errors are made in the presence of metalloprotease inhibitors. Thus, we performed immunocytochemical labeling of transverse frozen sections through the brain and retina of stage 35/36 embryos with a rabbit polyclonal antibody raised against a human ADAM10 peptide. The specificity of the antibody for XKUZ was confirmed by Western blot analysis (Fig. 7A) . Similar to what is observed in the rat cerebellum, a band of ϳ75 kDa was observed in Xenopus. Figure 7B ,C shows that XKUZ-like immunoreactivity is expressed both by RGC somata and by cells lining the optic tract, but is not present in the optic nerve or the brain neuropil.
Nonetheless, given that chick RGC axons have gelatinase activity (Sheffield and Graff, 1991) , it is likely that Xenopus RGC axons and growth cones also express metalloproteases. To test the possibility that the metalloprotease inhibitors could be acting on RGC growth cones directly, we examined whether GM6001 affected retinal growth cone morphology in culture, where there is no neuroepithelial substrate on which the metalloprotease inhibitors could act. We treated 1-d-old stage 24 retinal explant cultures with 5 M GM6001 for 24 hr and assayed RGC growth cone morphology. Importantly, RGCs are the only cells to send axons out of the eye explants. Neurite outgrowth from the GM6001-treated explant cultures was similar to that seen in controls. Consistent with this observation, GM6001 had no obvious effect on the morphology of growth cones in culture (Fig. 8 A,B) . A collapsed morphology was seen in 34.0% (n ϭ 194) and 34.6% (n ϭ 162) of growth cones in control and 5 M GM6001-treated cultures, respectively. Moreover, growth cones had similar numbers of filopodia (5.25 Ϯ 0.4, n ϭ 6 cultures in control; 5.18 Ϯ 0.3, n ϭ 5 cultures in GM6001) in the two treatment conditions. These data indicate that in the absence of a neuroepithelial substrate, metalloprotease inhibition did not affect RGC growth cone morphology or neurite extension.
An alternative explanation for the defects we observed in axon guidance is that GM6001 grossly disrupted the patterning and/or morphology of the neuroepithelium through which the RGC axons extend. However, short 3 hr applications of 5 M GM6001 did not impair RGC axon extension and/or guidance in vivo (Fig.  4C,D) . In addition, brains treated with a longer-term application of GM6001 for 24 hr were apparently normal (Fig. 8) . We performed immunolabeling of control and metalloprotease-treated brains with various neuroepithelial cell markers. These included antibodies that recognize: (1) general neuronal markers such as NCAM, Zn-12 (Fig. 8C,D) (Metcalfe et al., 1990) , (2) ␤-tubulin (Fig. 8 E) , (3) Islet-1, a lim homeodomain protein that is expressed by ventrally positioned neurons in the forebrain (Fig. 8 F) (Ericson et al., 1995) , and (4) a population of GABA-expressing neurons found at the guidance decision point in the middiencephalon, where RGC axons make their caudal turn toward the optic tectum (Roberts et al., 1987; Ferguson and McFarlane, 2002) (Fig. 8G,H ) . No obvious difference in the intensity or pattern of marker expression was observed between the control and GM6001-treated brains. 
Metalloproteases regulate the protein levels of the axon guidance receptor, DCC
Previous culture studies have suggested that the ectodomain of the Netrin receptor, DCC, is cleaved by metalloproteases, rendering the receptor inactive (Galko and Tessier-Lavigne, 2000) . In Xenopus, DCC is expressed both by RGC growth cones and by cells in the diencephalon through which the axons extend (de la Torre et al., 1997) . To determine whether metalloprotease inhibitors could influence the cleavage of DCC, transverse frozen sections through the forebrain and midbrain of embryos exposed to either 5 M GM6001 or control solution were processed for immunocytochemistry with a mouse monoclonal antibody against DCC (de la Torre et al., 1997) . The intensity of DCC immunolabeling of the neuropil on the treated side was measured (see Materials and Methods) and the GM6001-treated neuropil [63.5 Ϯ 9 (SEM); n ϭ 6] was 63% brighter ( p Ͻ 0.01; paired, two-tailed t test) than control (41.4 Ϯ 14; n ϭ 6). These data suggest that metalloproteases function in the Xenopus diencephalon to cleave at least one guidance receptor.
Metalloprotease inhibition results in target recognition errors by RGC axons
When GM6001 was applied to RGC axons as they first entered the ventral diencephalon, few axons innervated the optic tectum.
However, it was unclear whether the target-recognition defect was secondary to the earlier guidance errors made by the RGC axons in the mid-diencephalon. To determine whether metalloprotease activity is important for normal target recognition, 5 M GM6001 was applied to the developing optic projection at stage 37/38, just as the first axons reach the optic tectum. All control optic projections innervated the optic tectum normally (10 of 10), whereas in virtually all GM6001-treated brains a significant number of RGC axons failed to recognize their target and grew along its anterior border (10 of 11) (Fig. 9) . Thus, RGC axons make two key guidance errors when metalloprotease activity is inhibited; they fail to make a caudal turn in the mid-diencephalon and they ignore their normal midbrain target.
DISCUSSION
Our data suggest that metalloprotease activity is required in vivo for RGC axons to make appropriate guidance decisions at critical choice points. When metalloproteases were inhibited pharmacologically in an in vivo preparation, most RGC axons extended appropriately. However, axons failed to make the correct guidance decisions. First, RGC axons grew straight in the middiencephalon, where they normally make a caudal turn toward their target, the optic tectum. Second, many axons that reached Figure 6 . Defects in RGC axon pathfinding and target recognition caused by the application of BB-94. A, Qualitative description of the different defects in axon behavior observed in optic projections treated with BB-94. Numbers in parentheses represent the number of embryos. The description of the defects is the same as presented in the legend to Figure 2 . B, C, Control and BB-94-treated brains were exposed at stage 33/34 and fixed at stage 40. Measurements were made as described in the legend to Figure 3 . B, Effect on mean turning angle of increasing doses of BB-94. C, Dose-response of the effects of BB-94 on optic tract length (in micrometers). At lower concentrations, at which defects in pathfinding are observed, the extension of RGC axons is unaffected by BB-94. At the highest concentrations of BB-94, the optic projection is significantly shorter than in control exposed brains. *p Ͻ 0.05; **p Ͻ 0.01; ***p Ͻ 0.001; ANOVA, StudentNewmann-Keuls post hoc test. The numbers of embryos are shown in parentheses, and error bars are SEM.
the target boundary failed to enter the target and instead turned and grew along the anterior tectal border. At the higher doses of metalloprotease inhibitors, RGC axons were also impaired in their outgrowth. These in vivo data strongly support a role for metalloproteases in axon guidance and extension in the developing vertebrate visual system. Presumably, as suggested from culture experiments (Galko and Tessier-Lavigne, 2000; Hattori et al., 2000) , metalloproteases regulate the responsiveness of RGC axons to guidance cues by cleavage of the ectodomains of specific ligands or their receptors. In our study, the metalloprotease inhibitors would have access to both the axons and the neuroepithelium through which they travel. As such, metalloproteases may function in either the substrate or the axons, or perhaps both, to ensure proper guidance. Our data cannot differentiate between the two possibilities. XKUZ and several other metalloproteases are expressed in the Xenopus diencephalon around the time RGC axons are extending through the brain (Alfandari et al., 1997; Pan and Rubin, 1997; Cai et al., 1998; Damjanovski et al., 2000) . Conversely, embryonic vertebrate RGCs and their axons express metalloproteases (Sheffield and Graff, 1991; Sheffield et al., 1994; Canete Soler et al., 1995) . This is also true of many vertebrate growth cones extending in vitro (Nordstrom et al., 1995; Zuo et al., 1998; ChambautGuerin et al., 2000; Hayashita-Kinoh et al., 2001) . However, metalloprotease inhibitors had no obvious effect on the morphology of cultured Xenopus RGC growth cones. Although this would argue that metalloproteases do not operate within the growth cone, it is likely that the guidance receptors that would normally be cleaved by the metalloproteases do not function when axons are growing over a simplified laminin substrate. Indeed, metalloprotease inhibitors do affect the morphology of chick RGC growth cones growing on a more complicated tectal membrane substrate (Schlosshauer et al., 1990) . The metalloprotease inhibitors also had no effect on the general patterning of the neuroepithelium, but one might expect that they would affect only specific axon guidance molecules, such as we observed with DCC. Future molecular experiments manipulating the function of metalloproteases specifically in RGC axons, or the diencephalon, could address the issue of the site of metalloprotease activity. Despite the plethora of metalloproteases, the fact that axon guidance defects may be associated with individual metalloprotease mutants in Drosophila and mice indicates that such an approach may prove fruitful (Leighton et al., 2001; Schimmelpfeng et al., 2001) .
Several interesting candidate molecules might underlie the axon guidance defects we observed with the metalloprotease inhibitors. Three recognized guidance molecules for RGC axons are known to be cleaved by metalloproteases: Fibroblast growth factor receptors (FGFRs) (Levi et al., 1996) , DCC (Galko and Tessier-Lavigne, 2000) , and ephrins (Hattori et al., 2000) . All three are expressed in the developing Xenopus visual system and function in RGC axon guidance. Ephrins have been shown to function in the topographic mapping of vertebrate RGC axon projections (O'Leary and Wilkinson, 1999) and axon divergence at the Xenopus optic chiasm (Nakagawa et al., 2000) . However, no evidence suggests that they direct the proper trajectories of the axons in the diencephalon. Interestingly, treatment of posterior and anterior tectal membranes with metalloprotease inhibitors had no effect on the normal repulsive activity of posterior membranes for chick RGC axons (Schlosshauer et al., 1990) , despite the observation that metalloprotease inhibitors prolonged ephrin interactions with their ephrin receptors in mouse embryonic neuronal cultures (Hattori et al., 2000) .
The regulation of DCC signaling by metalloproteases has, in contrast, been demonstrated both in vitro and in vivo. For example, in Caenorhabditis elegans, genetic interactions were observed between mutants for MIG-17, a member of the ADAM family, and the worm Netrin ortholog UNC-6 (Nishiwaki et al., 2000) . In addition, Netrin-1-stimulated neurite outgrowth from rat embryonic spinal cord explants was potentiated by metalloprotease inhibitors (Galko and Tessier-Lavigne, 2000) . This effect was likely attributable to greater numbers of intact DCC receptors, because the metalloprotease inhibitors blocked DCC ectodomain shedding in DCC-transfected Chinese hamster ovary cells. Interestingly, DCC is expressed by both Xenopus RGC axons and the diencephalic neuroepithelium, suggesting that in our experiments the inhibitors could be acting on either population of receptors (de la Torre et al., 1997) . Although DCC is known to function in prompting RGC axons to leave the eye and in guidance at the optic chiasm (Deiner et al., 1997; Deiner and Sretavan, 1999) , its role in guiding axons at later points in the optic pathway is unknown. The expression of DCC mRNA in neuroepithelial cells in the middiencephalon and the border of the optic tectum (de la Torre et al., 1997) raises the possibility that normal metalloprotease-dependent regulation of DCC function is required in the substrate to direct RGC axons properly. Consistent with this, we found that after treatment with metalloprotease inhibitors, the brain neuropil was more brightly labeled with an antibody raised against the ectodomain of DCC.
Finally, we have shown previously that inhibiting RGC growth cone FGFRs caused the axons to avoid their tectal target in a manner similar to that observed with the metalloprotease inhibitors (McFarlane et al., 1996) . Previous studies have shown that MMP-2 can cleave the extracellular portion of the FGFR (Levi et al., 1996) . The neurotrophin tyrosine kinase receptor TrkA can be similarly processed by metalloproteases (Diaz-Rodriguez et al., 1999) . The cleavage results in the generation of cell-bound receptor fragments whose intracellular domain is constitutively tyrosine phosphorylated, and presumably leads to signal transduction downstream of the receptor. Possibly, a similar activation mechanism could occur with the ectodomain of the FGFR, also a receptor tyrosine kinase. If so, blocking metalloprotease activity and FGFR ectodomain shedding would produce targetrecognition defects similar to inhibiting FGFR function with a dominant negative receptor (McFarlane et al., 1996) . Although Xenopus MMP-2 has been identified, whether it is expressed at the right time to influence RGC FGFR signaling has not yet been determined (Jung et al., 2002) .
The fact that the higher metalloprotease inhibitor doses impaired RGC axon growth is not surprising given culture data showing that metalloprotease activity is required for axon extension. For instance, metalloprotease function promotes the extension of regenerating embryonic chick dorsal root ganglion neurites (Zuo et al., 1998) , and in Drosophila kuz mutants axons stall (Fambrough et al., 1996) . In addition, when rat pheochromocytoma cells that constitutively expressed stromelysin-1 antisense mRNA were induced to differentiate, their ability to extend neurites was significantly impaired (Nordstrom et al., 1995) . Metalloprotease-dependent promotion of extension could result from the ligand-independent activation of growth factor receptor . Defects in RGC axon target recognition caused by the late application of GM6001. Brains were exposed at stage 37/38 to either a control solution ( A) or 5 M GM6001 ( B-E), and optic projections were HRP-labeled at stage 40. Target-recognition defects are evident in the GM6001-treated brains. Axons grow dorsally along the anterior border of the optic tectum and then cross over the dorsal midline into the contralateral brain ( D). E is a higher-power view of the boxed area in C. Scale bars: C (for A-C), D, 50 m; E, 25 m.
